Patrick Soon-Shiong merges troubled 'moon shot' NantKwest and cell therapy play ImmunityBio in late-stage expansion

Kyle Blankenship

Once one of the hottest brands in biotech, Patrick Soon-Shiong’s next-gen cancer brainchild NantKwest has taken its lumps in recent years with little to show …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Patrick Soon-Shiong merges troubled 'moon shot' NantKwest and cell therapy play ImmunityBio in late-stage expansion

Kyle Blankenship

Sign up to read this article for free.

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Applied Therapeutics' rare disease drug gets a CRL

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Outlook's shares crash as wet AMD drug flunks Phase 3 test

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Patrick Soon-Sh­iong merges trou­bled 'moon shot' Nan­tK­west and cell ther­a­py play Im­mu­ni­ty­Bio in late-stage ex­pan­sion

Kyle Blankenship

Sign up to read this article for free.

more like this

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Out­look's shares crash as wet AMD drug flunks Phase 3 test

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Patrick Soon-Shiong merges troubled 'moon shot' NantKwest and cell therapy play ImmunityBio in late-stage expansion

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Applied Therapeutics' rare disease drug gets a CRL

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Outlook's shares crash as wet AMD drug flunks Phase 3 test

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M